6:00 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces the holding of oral presentations revealing the latest results obtained on AdoShell® Islets, an immunoprotective hydrogel containing Langerhans islets for the treatment of diabetes by cell therapy, during two international congresses: those of EASD and IPITA-IXA-CTRMS.
• The 59th annual congress of the EASD (European Association for the Study of Diabetes), which will be held from October 2 to 6, 2023, in Hamburg, Germany.
Title: ADO12, a novel allogeneic islet encapsulation device for islet transplantation without immunosuppression
• The joint congress of IPITA (The International Pancreas and Islet Transplant Association), IXA (the International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society), which will be held from October 26 to 29, 2023 , in San Diego, United States.
Title: How to administer a therapeutic dose of encapsulated human islets?